Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInterest Coverage RatioInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Barinthus Biotherapeutics (BRNS) Equity Average (2020 - 2025)

Barinthus Biotherapeutics' Equity Average history spans 6 years, with the latest figure at $79.4 million for Q4 2025.

  • For Q4 2025, Equity Average fell 45.16% year-over-year to $79.4 million; the TTM value through Dec 2025 reached $79.4 million, down 45.16%, while the annual FY2025 figure was $102.1 million, 35.58% down from the prior year.
  • Equity Average reached $79.4 million in Q4 2025 per BRNS's latest filing, down from $93.5 million in the prior quarter.
  • In the past five years, Equity Average ranged from a high of $254.0 million in Q2 2022 to a low of -$44.9 million in Q1 2021.
  • Average Equity Average over 5 years is $173.0 million, with a median of $185.4 million recorded in 2023.
  • Peak YoY movement for Equity Average: soared 948.0% in 2021, then tumbled 45.16% in 2025.
  • A 5-year view of Equity Average shows it stood at $247.5 million in 2021, then fell by 1.55% to $243.7 million in 2022, then decreased by 21.49% to $191.3 million in 2023, then dropped by 24.34% to $144.7 million in 2024, then crashed by 45.16% to $79.4 million in 2025.
  • Per Business Quant, the three most recent readings for BRNS's Equity Average are $79.4 million (Q4 2025), $93.5 million (Q3 2025), and $109.0 million (Q2 2025).